ReviewCureus2026
Clinical Impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) on Staging, Biochemical Recurrence Detection, and Treatment Decision-Making in Prostate Cancer.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific membrane antigen positron emission tomography (PSMA-PET) has transformed the imaging approach to prostate cancer (PCa) by enabling biologically targeted detection of disease beyond the capabilities of conventional anatomical imaging. This review examines the clinical impact of PSMA-PET in primary staging, detection of biochemical recurrence, and treatment decision-making, and discusses its integration into contemporary clinical practice. Compared with computed tomography (CT), magnetic resonance imaging (MRI), and bone scintigraphy, PSMA-PET demonstrates superior diagnostic accuracy for identifying nodal and distant metastatic disease, particularly in patients with intermediate- and high-risk tumors. In newly diagnosed disease, improved detection of small-volume metastases frequently alters treatment intent and guides the selection of local or systemic therapies. In the setting of biochemical recurrence, detection rates correlate strongly with prostate-specific antigen (PSA) levels, allowing earlier localization of recurrent disease and more individualized salvage strategies. PSMA-PET findings increasingly influence radiotherapy planning, selection of metastasis-directed therapies, and eligibility for targeted treatments. Major clinical guidelines now incorporate PSMA-PET into recommended staging and recurrence evaluation pathways. Despite these advances, important limitations remain, including false-positive findings, variability in interpretation, incomplete histologic confirmation, and limited evidence linking imaging-guided management changes to improved long-term outcomes. PSMA-PET represents a major advance in prostate cancer imaging by improving staging accuracy and enabling more personalized treatment strategies, while ongoing prospective studies aim to clarify its impact on survival and quality of care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.